Patients with advanced or metastasised non-small-cell lung cancer with Viscum album L. therapy in addition to PD-1/PD-L1 blockade: a real-world data study
Immunotherapy with PD-1/PD-L1 inhibitors has significantly improved the survival rates of patients with metastatic non-small-cell lung cancer (NSCLC). Results of a real-world data study investigating add-on VA (Viscum album L.) to chemotherapy have shown an association with the improved overall surv...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
22 April 2024
|
| In: |
Cancers
Year: 2024, Jahrgang: 16, Heft: 8, Pages: 1-19 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers16081609 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/cancers16081609 Verlag, kostenfrei, Volltext: https://www.mdpi.com/2072-6694/16/8/1609 
|
| Verfasserangaben: | Friedemann Schad, Anja Thronicke, Ralf-Dieter Hofheinz, Harald Matthes and Christian Grah |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1916169139 | ||
| 003 | DE-627 | ||
| 005 | 20250716225915.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250203s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers16081609 |2 doi | |
| 035 | |a (DE-627)1916169139 | ||
| 035 | |a (DE-599)KXP1916169139 | ||
| 035 | |a (OCoLC)1528018225 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schad, Friedemann |d 1969- |e VerfasserIn |0 (DE-588)122627563 |0 (DE-627)705976378 |0 (DE-576)293354855 |4 aut | |
| 245 | 1 | 0 | |a Patients with advanced or metastasised non-small-cell lung cancer with Viscum album L. therapy in addition to PD-1/PD-L1 blockade |b a real-world data study |c Friedemann Schad, Anja Thronicke, Ralf-Dieter Hofheinz, Harald Matthes and Christian Grah |
| 246 | 1 | |i Dieser Artikel gehört zum Special issue |a Immune checkpoint inhibitors, targeted therapies and adjuvant treatment of lung cancer | |
| 264 | 1 | |c 22 April 2024 | |
| 300 | |a 19 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.02.2025 | ||
| 520 | |a Immunotherapy with PD-1/PD-L1 inhibitors has significantly improved the survival rates of patients with metastatic non-small-cell lung cancer (NSCLC). Results of a real-world data study investigating add-on VA (Viscum album L.) to chemotherapy have shown an association with the improved overall survival of patients with NSCLC. We sought to investigate whether the addition of VA to PD-1/PD-L1 inhibitors in patients with advanced or metastasised NSCLC would have an additional survival benefit. In the present real-world data study, we enrolled patients from the accredited national registry, Network Oncology, with advanced or metastasised NSCLC. The reporting of data was performed in accordance with the ESMO-GROW criteria for the optimal reporting of oncological real-world evidence (RWE) studies. Overall survival was compared between patients receiving PD-1/PD-L1 inhibitor therapy (control, CTRL group) versus the combination of anti-PD-1/PD-L1 therapy and VA (combination, COMB group). An adjusted multivariate Cox proportional hazard analysis was performed to investigate variables associated with survival. From 31 July 2015 to 9 May 2023, 415 patients with a median age of 68 years and a male/female ratio of 1.2 were treated with anti-PD-1/PD-L1 therapy with or without add-on VA. Survival analyses included 222 (53.5%) patients within the CRTL group and 193 (46.5%) in the COMB group. Patients in the COMB group revealed a median survival of 13.8 months and patients in the CRTL group a median survival of 6.8 months (adjusted hazard ratio, aHR: 0.60, 95% CI: 0.43-0.85, p = 0.004) after adjustment for age, gender, tumour stage, BMI, ECOG status, oncological treatment, and PD-L1 tumour proportion score. A reduction in the adjusted hazard of death by 56% was seen with the addition of VA (aHR 0.44, 95% CI: 0.26-0.74, p = 0.002) in patients with PD-L1-positive tumours (tumour proportion score > 1%) treated with first-line anti-PD-1/PD-L1 therapy. Our findings suggest that add-on VA correlates with improved survival in patients with advanced or metastasised NSCLC who were treated with PD-1/PD-L1 inhibitors irrespective of age, gender, tumour stage, or oncological treatment. The underlying mechanisms may include the synergistic modulation of the immune response. A limitation of this study is the observational non-randomised study design, which only allows limited conclusions to be drawn and prospective randomised trials are warranted. | ||
| 650 | 4 | |a <i>Viscum album</i> L. extracts | |
| 650 | 4 | |a lung cancer | |
| 650 | 4 | |a non-small-cell lung cancer | |
| 650 | 4 | |a PD-1 inhibitor | |
| 650 | 4 | |a PD-L1 inhibitor | |
| 650 | 4 | |a real-world data study | |
| 650 | 4 | |a survival | |
| 700 | 1 | |a Thronicke, Anja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 700 | 1 | |a Matthes, Harald |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grah, Christian |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 16(2024), 8, Artikel-ID 1609, Seite 1-19 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a Patients with advanced or metastasised non-small-cell lung cancer with Viscum album L. therapy in addition to PD-1/PD-L1 blockade a real-world data study |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:8 |g elocationid:1609 |g pages:1-19 |g extent:19 |a Patients with advanced or metastasised non-small-cell lung cancer with Viscum album L. therapy in addition to PD-1/PD-L1 blockade a real-world data study |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers16081609 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/16/8/1609 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250203 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 3 | ||
| 999 | |a KXP-PPN1916169139 |e 4660020991 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"22 April 2024"}],"recId":"1916169139","type":{"media":"Online-Ressource","bibl":"article-journal"},"titleAlt":[{"title":"Immune checkpoint inhibitors, targeted therapies and adjuvant treatment of lung cancer"}],"id":{"doi":["10.3390/cancers16081609"],"eki":["1916169139"]},"physDesc":[{"extent":"19 S."}],"relHost":[{"id":{"eki":["614095670"],"issn":["2072-6694"],"zdb":["2527080-1"]},"disp":"Patients with advanced or metastasised non-small-cell lung cancer with Viscum album L. therapy in addition to PD-1/PD-L1 blockade a real-world data studyCancers","physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 27.05.2020"],"origin":[{"publisherPlace":"Basel","publisher":"MDPI","dateIssuedDisp":"2009-","dateIssuedKey":"2009"}],"recId":"614095670","type":{"bibl":"periodical","media":"Online-Ressource"},"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"pubHistory":["1.2009 -"],"title":[{"title":"Cancers","title_sort":"Cancers"}],"language":["eng"],"part":{"pages":"1-19","extent":"19","issue":"8","volume":"16","text":"16(2024), 8, Artikel-ID 1609, Seite 1-19","year":"2024"}}],"note":["Gesehen am 03.02.2025"],"name":{"displayForm":["Friedemann Schad, Anja Thronicke, Ralf-Dieter Hofheinz, Harald Matthes and Christian Grah"]},"person":[{"family":"Schad","role":"aut","given":"Friedemann","display":"Schad, Friedemann"},{"family":"Thronicke","display":"Thronicke, Anja","given":"Anja","role":"aut"},{"display":"Hofheinz, Ralf-Dieter","role":"aut","given":"Ralf-Dieter","family":"Hofheinz"},{"family":"Matthes","display":"Matthes, Harald","given":"Harald","role":"aut"},{"given":"Christian","role":"aut","display":"Grah, Christian","family":"Grah"}],"title":[{"title_sort":"Patients with advanced or metastasised non-small-cell lung cancer with Viscum album L. therapy in addition to PD-1/PD-L1 blockade","title":"Patients with advanced or metastasised non-small-cell lung cancer with Viscum album L. therapy in addition to PD-1/PD-L1 blockade","subtitle":"a real-world data study"}],"language":["eng"]} | ||
| SRT | |a SCHADFRIEDPATIENTSWI2220 | ||